deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03788434

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (CONSORTIUM)

CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection

Sponsor: Vedanta Biosciences, Inc.

Conditions CDI Clostridioides Difficile Clostridioides Difficile Infection Clostridioides Difficile Infection Recurrence Clostridium Difficile Clostridium Difficile Infection Clostridium Difficile Infection Recurrence
Interventions Placebo VE303
Updated 19 times since 2019 Last updated: Jun 29, 2023 Started: Feb 8, 2019 Primary completion: Jun 2, 2021 Completion: Sep 15, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on CDI and Clostridioides Difficile, this trial is completed. The trial is conducted by Vedanta Biosciences, Inc. and has accumulated 19 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Aug 2023 · 22 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Oct 2021 — Aug 2023 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  2. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Feb 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  7. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  9. Oct 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  11. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  12. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  13. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  14. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vedanta Biosciences, Inc.
Data source: Vedanta Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annapolis, United States , Boston, United States , Calgary, Canada , Canoga Park, United States , Cedar Park, United States , Chicoutimi, Canada , Clearwater, United States , DuBois, United States , Fort Worth, United States , Gainesville, United States and 23 more locations